In this pilot study, we conducted an assessment on a limited number of clinical samples available to us -- to evaluate the feasibility of using a multiplex immunohistochemistry-based tool to ultimately predict response to therapy and overall survival outcome in patients diagnosed with melanoma and subsequently treated with anti-PD1 immune checkpoint inhibitors -- based upon their Nodal expression profile. Here, PDCD1 is linked to melanoma.